INmune Bio (INMB) Competitors $6.45 -0.27 (-4.02%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INMB vs. KURA, CRGX, HUMA, PHVS, ANNX, KROS, MREO, RAPP, DNA, and TRDAShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Kura Oncology (KURA), CARGO Therapeutics (CRGX), Humacyte (HUMA), Pharvaris (PHVS), Annexon (ANNX), Keros Therapeutics (KROS), Mereo BioPharma Group (MREO), Rapport Therapeutics (RAPP), Ginkgo Bioworks (DNA), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Kura Oncology CARGO Therapeutics Humacyte Pharvaris Annexon Keros Therapeutics Mereo BioPharma Group Rapport Therapeutics Ginkgo Bioworks Entrada Therapeutics INmune Bio (NASDAQ:INMB) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation. Do institutionals & insiders hold more shares of INMB or KURA? 12.7% of INmune Bio shares are held by institutional investors. 35.2% of INmune Bio shares are held by insiders. Comparatively, 5.5% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in INMB or KURA? Kura Oncology received 285 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.09% of users gave INmune Bio an outperform vote while only 69.44% of users gave Kura Oncology an outperform vote. CompanyUnderperformOutperformINmune BioOutperform Votes14076.09% Underperform Votes4423.91% Kura OncologyOutperform Votes42569.44% Underperform Votes18730.56% Do analysts recommend INMB or KURA? INmune Bio presently has a consensus price target of $20.00, suggesting a potential upside of 210.08%. Kura Oncology has a consensus price target of $27.38, suggesting a potential upside of 277.07%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Kura Oncology 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Does the media favor INMB or KURA? In the previous week, Kura Oncology had 3 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Kura Oncology and 0 mentions for INmune Bio. Kura Oncology's average media sentiment score of 0.02 beat INmune Bio's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media. Company Overall Sentiment INmune Bio Neutral Kura Oncology Neutral Which has more volatility and risk, INMB or KURA? INmune Bio has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Is INMB or KURA more profitable? Kura Oncology's return on equity of -44.09% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -117.48% -78.96% Kura Oncology N/A -44.09%-39.57% Which has better valuation & earnings, INMB or KURA? INmune Bio has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$160K893.73-$30.01M-$2.18-2.96Kura OncologyN/AN/A-$152.63M-$2.36-3.08 SummaryINmune Bio beats Kura Oncology on 9 of the 17 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.00M$2.96B$5.21B$9.15BDividend YieldN/A1.94%5.13%4.03%P/E Ratio-2.9644.8187.9017.36Price / Sales893.73287.561,245.5478.03Price / CashN/A192.9043.7535.97Price / Book3.123.965.314.79Net Income-$30.01M-$41.02M$122.62M$225.00M7 Day Performance-1.38%0.19%0.58%2.62%1 Month Performance46.59%-1.72%2.54%3.81%1 Year Performance-43.12%-2.23%25.49%20.10% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.564 of 5 stars$6.45-4.0%$20.00+210.1%-43.1%$143.00M$160,000.00-2.9610KURAKura Oncology4.3102 of 5 stars$7.15-2.3%$27.38+282.9%-50.6%$556.01MN/A-3.03130Short Interest ↑CRGXCARGO Therapeutics1.7591 of 5 stars$11.90-11.9%$31.80+167.2%-40.4%$547.73MN/A-2.79116Positive NewsGap DownHUMAHumacyte2.8898 of 5 stars$4.33-6.1%$13.71+216.7%+65.2%$544.97M$1.57M-3.23150Analyst RevisionPHVSPharvaris2.5567 of 5 stars$17.03-4.3%$39.25+130.5%-32.7%$542.24MN/A-6.0830Positive NewsGap DownHigh Trading VolumeANNXAnnexon2.2197 of 5 stars$4.84+0.2%$15.80+226.4%-3.2%$515.92MN/A-4.6160KROSKeros Therapeutics3.2119 of 5 stars$12.66-13.0%$75.00+492.4%-79.5%$512.82M$651,000.00-2.43100Analyst ForecastGap UpMREOMereo BioPharma Group2.2374 of 5 stars$3.25-8.5%$7.83+141.0%-9.4%$504.22M$1M0.0040RAPPRapport Therapeutics2.1003 of 5 stars$13.72-7.4%$35.00+155.1%N/A$501.82MN/A0.00N/ADNAGinkgo Bioworks0.6181 of 5 stars$8.68-11.2%$4.58-47.3%N/A$498.92M$217.11M-0.661,218TRDAEntrada Therapeutics2.7381 of 5 stars$13.29-9.3%$25.67+93.1%-13.4%$497.31M$215.23M8.36110Positive News Related Companies and Tools Related Companies Kura Oncology Competitors CARGO Therapeutics Competitors Humacyte Competitors Pharvaris Competitors Annexon Competitors Keros Therapeutics Competitors Mereo BioPharma Group Competitors Rapport Therapeutics Competitors Ginkgo Bioworks Competitors Entrada Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INMB) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INMB Stock Alerts